ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Abbisko Cayman and Merck KGaA, Darmstadt, Germany side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Abbisko CaymanMerck KGaA, Darmstadt, Germany
studies on the registry38523
open to participants now1917
phase 3 studies under way17
reach primary completion within a year37
programswith a study of their own in two years814

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAbbisko CaymanMerck KGaA, Darmstadt, Germany
Phase 1

Abbisko Cayman: 2 of its 8 programs at phase 1

  1. ABSK131phase 1
  2. ABSK211phase 1
25%

Merck KGaA, Darmstadt, Germany: 6 of its 14 programs at phase 1

  1. PARP1 Inhibitor HRS-1167phase 1
  2. M5542phase 1
  3. Anti-MUC-1/Anti-CD40 Bispecific Antibody M0324phase 1
  4. M7437phase 1
  5. Contraceptives, Oral, Combinedphase 1

and 1 more — sign in to see them all

43%
Phase 2

Abbisko Cayman: 5 of its 8 programs at phase 2

  1. irpagratinibphase 2
  2. PD-L1 Inhibitor ABSK043phase 2
  3. ABSK061phase 2
  4. ABSK141phase 2
  5. glecirasibphase 2
63%

Merck KGaA, Darmstadt, Germany: 2 of its 14 programs at phase 2

  1. mirdametinibphase 2
  2. pimicotinibphase 2
14%
Phase 3

Abbisko Cayman: 1 of its 8 programs at phase 3

  1. pimicotinibphase 3
13%

Merck KGaA, Darmstadt, Germany: 3 of its 14 programs at phase 3

  1. enpatoranphase 3
  2. precemtabart tocentecanphase 3
  3. evobrutinibphase 3
21%
Approved, new studies00%

Merck KGaA, Darmstadt, Germany: 3 of its 14 programs at approved, new studies

  1. nirogacestatapproved, new study
  2. follitropin alfaapproved, new study
  3. lutropin alfaapproved, new study
21%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Abbisko Cayman2 readouts · 0 phase 3·······

Abbisko Cayman, Jun ’27: 1 program whose next study reaches primary completion

  1. irpagratinibphase 2 · Jun 30 · NCT07327034

Abbisko Cayman, Jul ’27: 1 program whose next study reaches primary completion

  1. PD-L1 Inhibitor ABSK043phase 2 · Jul 30 · NCT04964375
···
Merck KGaA, Darmstadt, Germany5 readouts · 2 phase 3

Merck KGaA, Darmstadt, Germany, Nov ’26: 1 program whose next study reaches primary completion

  1. mirdametinibphase 2 · Nov 27 · NCT06997276
··

Merck KGaA, Darmstadt, Germany, Feb ’27: 1 program whose next study reaches primary completion

  1. PARP1 Inhibitor HRS-1167phase 1 · Feb 22 · NCT06421935
··

Merck KGaA, Darmstadt, Germany, May ’27: 1 program whose next study reaches primary completion

  1. nirogacestatapproved, new study · May 28 · NCT07170644
···

Merck KGaA, Darmstadt, Germany, Sep ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. follitropin alfaapproved, new study · Sep 30 · NCT07340827
  2. lutropin alfaapproved, new study · Sep 30 · NCT07340827
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Abbisko Cayman

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 2

Merck KGaA, Darmstadt, Germany

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 5 in all. A program counts in each condition its studies name most.

ConditionAbbisko CaymanMerck KGaA, Darmstadt, Germany
Carcinoma, Non-Small-Cell Lungboth · compare here

Abbisko Cayman in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. PD-L1 Inhibitor ABSK043phase 2
  2. glecirasibphase 2

Their studies: Abbisko Cayman’s studies of Carcinoma, Non-Small-Cell Lung in search

Merck KGaA, Darmstadt, Germany in Carcinoma, Non-Small-Cell Lung: 1 program

  1. mirdametinibphase 2

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Carcinoma, Non-Small-Cell Lung in search

Neoplasmsboth · compare here

Abbisko Cayman in Neoplasms: 2 programs

  1. pimicotinibphase 3
  2. PD-L1 Inhibitor ABSK043phase 2

Their studies: Abbisko Cayman’s studies of Neoplasms in search

Merck KGaA, Darmstadt, Germany in Neoplasms: 1 program

  1. pimicotinibphase 2

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Neoplasms in search

Pancreatic Neoplasmsboth · compare here

Abbisko Cayman in Pancreatic Neoplasms: 2 programs

  1. pimicotinibphase 3
  2. glecirasibphase 2

Their studies: Abbisko Cayman’s studies of Pancreatic Neoplasms in search

Merck KGaA, Darmstadt, Germany in Pancreatic Neoplasms: 1 program

  1. pimicotinibphase 2

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Pancreatic Neoplasms in search

Giant Cell Tumor of Tendon Sheathboth · compare here

Abbisko Cayman in Giant Cell Tumor of Tendon Sheath: 1 program

  1. pimicotinibphase 3

Their studies: Abbisko Cayman’s studies of Giant Cell Tumor of Tendon Sheath in search

Merck KGaA, Darmstadt, Germany in Giant Cell Tumor of Tendon Sheath: 1 program

  1. pimicotinibphase 2

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Giant Cell Tumor of Tendon Sheath in search

Synovitis, Pigmented Villonodularboth · compare here

Abbisko Cayman in Synovitis, Pigmented Villonodular: 1 program

  1. pimicotinibphase 3

Their studies: Abbisko Cayman’s studies of Synovitis, Pigmented Villonodular in search

Merck KGaA, Darmstadt, Germany in Synovitis, Pigmented Villonodular: 1 program

  1. pimicotinibphase 2

Their studies: Merck KGaA, Darmstadt, Germany’s studies of Synovitis, Pigmented Villonodular in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetAbbisko CaymanMerck KGaA, Darmstadt, Germany
CSF1Rpimicotinibrulepimicotinibrule
A target, or a pathogen for a vaccine, known for: Abbisko Cayman 4 of 8 · Merck KGaA, Darmstadt, Germany 9 of 14 programs (13 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.